Critical Duration of Intracellular Ca2+ Response Required for Continuous Translocation and Activation of Cytosolic Phospholipase A2*

Tetsuya HirabayashiDagger §, Kazuhiko KumeDagger , Kenzo Hirose, Takehiko YokomizoDagger , Masamitsu Iino, Hiroshi Itoh§, and Takao ShimizuDagger parallel

From the Dagger  Department of Biochemistry and Molecular Biology,  Department of Pharmacology, Faculty of Medicine, University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033 and the § Department of Biological Sciences, Faculty of Bioscience and Biotechnology, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8501, Japan

    ABSTRACT
Top
Abstract
Introduction
References

When cells are exposed to certain external stimuli, arachidonic acid (AA) is released from the membrane and serves as a precursor of various types of eicosanoids. A Ca2+-regulated cytosolic phospholipase A2 (cPLA2) plays a dominant role in the release of AA. To closely examine the relation between Ca2+ response and AA release by stimulation of G protein-coupled receptors, we established several lines of Chinese hamster ovary cells expressing platelet-activating factor receptor or leukotriene B4 receptor. Measurement of intracellular Ca2+ concentration ([Ca2+]i) demonstrated that cell lines capable of releasing AA elicited a sustained [Ca2+]i increase when stimulated by agonists. The prolonged [Ca2+]i elevation is the result of Ca2+ entry, because this elevation was blocked by EGTA treatment or in the presence of Ca2+ channel blockers (SKF 96365 and methoxyverapamil). cPLA2 fused with a green fluorescent protein (cPLA2-GFP) translocated from the cytosol to the perinuclear region in response to increases in [Ca2+]i. When EGTA was added shortly after [Ca2+]i increase, the cPLA2-GFP returned to the cytosol, without liberating AA. After a prolonged [Ca2+]i increase, even by EGTA treatment, the enzyme was not readily redistributed to the cytosol. Thus, we propose that a critical time length of [Ca2+]i elevation is required for continuous membrane localization and full activation of cPLA2.

    INTRODUCTION
Top
Abstract
Introduction
References

Arachidonic acid (AA)1 is a precursor for biosynthesis of eicosanoids, including prostaglandins, thromboxanes, leukotrienes, and lipoxins. In the resting state, the bulk of the AA in mammalian cells is esterified in glycerophospholipids at the sn-2 position (1). Liberation of AA occurs mainly by activation of phospholipase A2 (PLA2) in response to varieties of extracellular stimuli such as cytokines, hormones, neurotransmitters, mitogens, antigens, and endotoxins (2). Mammalian cells have structurally diverse forms of PLA2 including secretory PLA2, Ca2+-independent PLA2, and cytosolic PLA2 (cPLA2) (3-5). Among these PLA2s, receptor-mediated AA release is primarily attributed to cPLA2 because the enzyme preferentially hydrolyzes phospholipids containing AA and is regulated by physiological levels of intracellular calcium concentrations ([Ca2+]i) and phosphorylation of Ser-505 by mitogen-activated protein kinase (MAPK) (6-9). Consistently, stimulated peritoneal macrophages derived from cPLA2-deficient mice fail to produce eicosanoids (10, 11). Sensitivity of cPLA2 to Ca2+ is mediated through an amino-terminal CaLB domain which is homologous to the C2 domain of protein kinase C and several other Ca2+-dependent phospholipid-binding proteins (6, 12). Immunofluorescent studies have shown that cPLA2 translocates from the cytosol to the nuclear envelope and the endoplasmic reticulum in response to [Ca2+]i increase (13, 14). Other proteins involved in eicosanoid production, such as cyclooxygenase isoforms (15-17), 5-lipoxygenase, 5-lipoxygenase-activating protein, and leukotriene C4 synthase (18-20) are also localized to these sites constitutively or upon cell stimulation.

The mobilization of Ca2+ can be elicited by ligand binding to cell-surface receptors that activate phospholipase Cs through heterotrimeric G protein-dependent or protein tyrosine kinase-dependent pathway. Calcium signaling patterns occur as single transients, repetitive oscillations, or sustained plateaux. Although several investigators have noted the importance of Ca2+ influx in receptor-mediated AA release (21-23), little is known about how these Ca2+ signaling patterns regulate cPLA2 translocation and AA release.

To address this question, we monitored Ca2+ signaling pattern, cPLA2 translocation, and AA release using Chinese hamster ovary (CHO) cell lines stably expressing platelet-activating factor (PAF) receptor (24) and/or leukotriene B4 (LTB4) receptor (25). In CHO cells, cPLA2 is expressed endogenously and coupled to receptor-mediated release of AA (26, 27). We found that a critical time length of [Ca2+]i elevation is required for continuous translocation of cPLA2 to the membrane and for the release of AA.

    EXPERIMENTAL PROCEDURES

Materials-- The sources of materials used in this work were as follows: PAF C-16 from Cayman Chemical (Ann Arbor, MI); cremophore EL from Sigma; [3H]arachidonic acid, [3H]WEB 2086, and [3H]leukotriene B4 from NEN Life Science Products; fura-2 acetoxymethyl from Dojindo (Kumamoto, Japan); SKF 96365, ionomycin, and nifedipine from Calbiochem; methoxyverapamil from RBI (Natick, MA); anti-cPLA2 monoclonal IgG (4-4B-3C) from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA); and fatty acid-free bovine serum albumin fraction V from Bayer (Kankakee, IL).

WEB 2086 and leukotriene B4 were generous gifts from Boehringer Ingelheim (Germany) and Drs. Y. Kobayashi and F. Sato (Tokyo Institute of Technology), respectively.

Plasmid Construction-- For a chimeric protein containing GFP at the carboxyl terminus of cPLA2, cDNA encoding human cPLA2 was amplified by polymerase chain reaction with primers upstream (5'-GGAAGATCTATGTCATTTATAGATCCTT-3') and downstream (5'-TGCGGTCGACTGCTTTGGGTTTACTTAGA-3') using pSV2-cPLA2 (provided by Drs. I. Kudo and M. Murakami, Showa University, Tokyo) as a template. The resulting polymerase chain reaction product was cloned into BglII-SalI sites of pEGFP-N3 vector (, Palo Alto, CA) to obtain a cPLA2-GFP fusion construct. The orientation of cPLA2 and the integrity of the reading frame was verified by restriction analysis and DNA sequencing.

Cell Culture and Transfection-- CHO-K1 cells were maintained under 5% CO2 at 37 °C in growth medium (Ham's F12 medium supplemented with 10% fetal calf serum, 50 units/ml penicillin, and 50 µg/ml streptomycin). CHO cells stably expressing PAF receptor or LTB4 receptor were generated as described previously (25, 28). Briefly, cDNAs of guinea pig PAF receptor and human LTB4 receptor were subcloned into mammalian expression vectors, pcDNAI/Neo and pcDNA3 (Invitrogen, Carlsbad, CA), respectively, and transfected into CHO-K1 cells. Clones resistant to Geneticin (1 mg/ml) were isolated by limiting dilution, tested for receptor expressions by binding assay, and maintained in the presence of 0.3 mg/ml Geneticin. PAF-LT cells were generated by co-transfection of PAF11 cells expressing PAF receptor (see below) with the expression vector for LTB4 receptor and pPUR encoding the puromycin resistance gene (), and by selection with puromycin (10 µg/ml, Sigma).

For cPLA2-GFP expression, cells were seeded at a density of 5 × 105 cells/60-mm dishes and transiently transfected with 2 µg of the expression vector encoding a cPLA2-GFP fusion protein (pcPLA2-GFP) or a control vector pEGFP-N3 with LipofectAMINE PLUS (Life Technologies, Inc.), according to the manufacturer's protocol, and used for experiments 48-72 h after transfection. The amount of cPLA2-GFP was comparable to that of endogenous cPLA2, as determined by immunoblotting with anti-cPLA2 antibody (data not shown).

Binding Assay-- Binding assays for the PAF receptor or the LTB4 receptor on CHO-K1 cells were performed as described previously (29). Briefly, cells on a 24-well culture plate were incubated for 1 h at 25 °C with various concentrations of [3H]WEB 2086 or [3H]LTB4 in the presence or absence of unlabeled ligand (20 µM WEB 2086 or 4 µM LTB4, respectively). The cells were washed three times with Hepes/Tyrode's/BSA buffer (140 mM NaCl, 2.7 mM KCl, 1.8 mM CaCl2, 0.49 mM MgCl2, 5.6 mM D-glucose, 12 mM NaHCO3, 0.37 mM NaH2PO4, 10 mM Hepes (pH 7.4), and 0.1% (w/v) fatty acid-free BSA) and then lysed in 1% Triton X-100. The radioactivity of the cell lysate was determined by liquid scintillation counting. Kd and Bmax values were calculated by Scatchard analysis.

Single Cell Calcium Imaging-- 4 × 104 cells were seeded on coverslips (16-mm diameter) in the growth medium and incubated for 24 h. After another 24 h incubation in serum-free medium containing 0.1% (w/v) fatty acid-free BSA, the cells were washed twice with Hepes/Tyrode's/BSA buffer and incubated at 37 °C with 10 µM fura-2 acetoxymethyl ester and 0.01% (w/v) cremophore EL for 1 h in the buffer. After loading, cells were washed with and maintained in the same buffer in the dark at room temperature. Fura-2 fluorescence intensity was measured by alternating excitation at 340 and 380 nm and detecting emission at 505 nm with a 40× objective (Nikon UV-fluor), an SIT camera, and an ARGUS-50/CA image processor (Hamamatsu Photonics, Hamamatsu, Japan). To determine intracellular free Ca2+ concentrations, the 340/380 ratio of fluorescence intensities were compared with the ratio for Ca2+ standard in solution (Molecular Probes, Eugene, OR).

AA Release Assay-- Cells were seeded onto 12-well culture plates at a density of 8 × 104 cells/well in the growth medium. After 24 h incubation, the medium was removed, and the cells were labeled by incubation for 24 h in 0.75 ml of serum-free medium containing 3.7 kBq of [3H]arachidonic acid (3.7 TBq/mmol) and 0.1% (w/v) fatty acid-free BSA. The cells were then washed three times with Hepes/Tyrode's/BSA buffer and stimulated with ligands or ionomycin in the same buffer at 37 °C. Radioactivity of supernatants and cell lysates (in 1% Triton X-100) were measured by liquid scintillation counting. The amount of the radioactivity released into the supernatant was expressed as a percentage of the total incorporated radioactivity.

Confocal Microscopy-- Cells transfected with pcPLA2-GFP were seeded on coverslips (14-mm diameter) of glass-bottomed culture dishes (Matsunami, Osaka, Japan) at a density of 2.6 × 104 and serum-starved as described above. The culture medium was replaced with Hepes/Tyrode's/BSA buffer, and fluorescence images were taken in a FLUOVIEW confocal laser scanning microscope system (Olympus, Tokyo) with a 100× oil immersion objective (NA 1.35), 488-nm laser line for excitation and a 520 ± 20-nm band pass filter for emission.

    RESULTS

Agonist-induced Calcium Response and AA Release in CHO Cells Expressing PAF or LTB4 Receptor-- Guinea pig PAF receptor and human LTB4 receptor were expressed in CHO-K1 cells that have no detectable endogenous receptors. Six cell lines PAF11, PAF12, PAF14, LT13, LTF2, and PAF-LT were examined for binding assay, agonist-induced Ca2+ response (Fig. 1), and AA release. Results obtained using these cell lines are summarized in Table I. In cells with low levels of receptor expression (PAF12 and LT13 cells), stimulation with agonists caused a rapid and transient [Ca2+]i increase, which returned to the base line within 2-5 min (Fig. 1, B and F). These cell lines did not release AA in response to PAF or LTB4. On the other hand, in cells with high levels of receptor expression (PAF11, PAF14 and LTF2 cells), stimulation with agonists induced a sustained [Ca2+]i increase which remained elevated at least for 5 min (Fig. 1, A, C, and E) and AA release. In PAF-LT cell line with a high level of PAF receptor and a low level of LTB4 receptor expression, PAF induced a sustained [Ca2+]i increase (Fig. 1D) and AA release, whereas LTB4 induced a transient [Ca2+]i increase (Fig. 1G) and little AA release. These results suggest that the sustained [Ca2+]i increase is necessary for receptor-mediated AA release from CHO cells.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 1.   Ca2+ response in CHO cell lines with different levels of receptor expression. Fura-2-loaded cells were stimulated with 100 nM PAF or 1 µM LTB4 in the presence of 1.8 mM extracellular Ca2+. [Ca2+]i was calculated from 340/380 ratios obtained from groups of 5-10 cells as described under "Experimental Procedures."

                              
View this table:
[in this window]
[in a new window]
 
Table I
Expression and downstream signals of PAF and LTB4 receptor in CHO cell lines
Bmax and Kd values for each line were determined by Scatchard analysis of the binding of [3H]WEB 2086 or [3H]LTB4 to the cells. Ca2+ response to 100 nM PAF or 1 µM LTB4 was measured as described under "Experimental Procedures." S represents a sustained [Ca2+]i increase that continued over 5 min; T represents a transient [Ca2+]i increase that returned to the base line within 5 min. AA release 10 min after stimulation (100 nM PAF or 1 µM LTB4) was measured, and the values were subtracted with background releases without stimulation and expressed as the means ± S.D. from triplicate determinations.

Requirement of Calcium Influx for AA Release-- PAF11 cells with a relatively higher receptor expression were used in the following studies. 100 nM PAF induced AA release in the time course shown in Fig. 2A. It had a 2-min lag phase, followed by a linear increase up to 10 min. PAF induced AA release in a dose-dependent manner, and ED50 was around 4 × 10-10 M (Fig. 2B).


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 2.   AA release from PAF11 cells. A, time course of PAF-induced AA release from PAF11 cells. [3H]AA-labeled cells were unstimulated (open circle) or stimulated (filled circle) with 100 nM PAF at 37 °C. B, dose-response curve for AA release. Cells were stimulated with PAF for 10 min. The values are the means ± S.D. of three experiments.

We next examined contributions of intracellular and extracellular Ca2+ sources in the agonist-induced Ca2+ response and AA release. PAF stimulation in the presence of either Ca2+ chelator EGTA (10 mM) or Ca2+ channel blockers (50 µM SKF 96365 or 100 µM methoxyverapamil) (30, 31) evoked a transient [Ca2+]i increase which returned to the base line within 2 min (Fig. 3, A-D). Thus, the initial rise in [Ca2+]i is attributed to release from the intracellular Ca2+ pool, whereas the sustained elevation requires Ca2+ influx. Fig. 4A shows that lowering extracellular Ca2+ concentration or depriving Ca2+ by EGTA reduced PAF-stimulated AA release, whereas increasing its concentration enhanced the release. Pretreatment of the cells with SKF 96365 or methoxyverapamil inhibited PAF-induced AA release (Fig. 4B), indicating that the Ca2+ influx is required for AA release.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 3.   Inhibition of PAF-induced Ca2+ influx by EGTA, SKF 96365, or methoxyverapamil. PAF11 cells were untreated (A) or pretreated for 5 min with 10 mM EGTA (B), 50 µM SKF 96365 (C), or 100 µM (±)-methoxyverapamil (D) and stimulated with 100 nM PAF.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 4.   Effects of extracellular Ca2+ concentrations ([Ca2+]o) and Ca2+ channel blockers on PAF-induced AA release. A, PAF11 cells labeled with [3H]AA were incubated for 5 min in the buffer containing 0.18, 1.8, or 18 mM CaCl2 with or without EGTA and stimulated with 100 nM PAF for 15 min. B, PAF11 cells were pretreated with SKF 96365 or (±)-methoxyverapamil as described above and stimulated with 100 nM PAF for 10 min. Columns and vertical bars denote the mean ± S.D. of three experiments.

Critical Length of [Ca2+]i Elevation for AA Release-- EGTA was applied at various time points before and after PAF stimulation in order to terminate [Ca2+]i elevation. Single cell Ca2+ imaging confirmed that addition of EGTA after PAF stimulation created a transient [Ca2+]i increase, which returned to the base line within 1 min following the addition (Fig. 5A). Fig. 5C shows that EGTA added 1 min after PAF stimulation substantially inhibited the PAF-induced AA release but did not alter the AA release when added 5 min after the stimulation.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 5.   AA release is dependent on duration of [Ca2+]i rise. A and B, transient or sustained Ca2+ responses were induced by 100 nM PAF (A) or 2 µM ionomycin (B) with or without the addition of 10 mM EGTA at the time point indicated. C and D, EGTA (10 mM) was added to PAF11 cells at various time points before and after stimulation with 100 nM PAF (C) or 2 µM ionomycin (D). AA release 10 min after stimulation was determined as in Fig. 2. Data are the means ± S.D. of three experiments. E, as in C, except that the cells were transiently transfected with GFP expression vector pEGFP-N3 (open circle) or the expression vector for cPLA2-GFP (filled circle).

Since stimulation of the PAF receptor results in various signals besides [Ca2+]i elevation (32), similar experiments were carried out using a Ca2+ ionophore ionomycin to study the role of Ca2+ signaling in a more direct manner. The prolonged [Ca2+]i increase was generated by 2 µM ionomycin and had about the same magnitude as the PAF-stimulated plateau (Fig. 5B). The transient [Ca2+]i increase was created by ionomycin with the following addition of EGTA, and this increase returned to the base line within 1 min after the addition (Fig. 5B). The ionomycin-induced sustained [Ca2+]i rise caused AA release, whereas the brief [Ca2+]i rise did not (Fig. 5D), confirming that a prolonged [Ca2+]i increase (over 2 min) is essential for AA release.

Translocation and Reversal of cPLA2 by the Change in [Ca2+]i-- Due to its inherent fluorescence and unique compact structure, green fluorescent protein (GFP) has been reported in many studies to serve as a valuable reporter in the localization of various proteins without interfering with their biological activity (33). We constructed a chimeric protein cPLA2-GFP by fusing EGFP to the carboxyl terminus of cPLA2. To ensure that the fusion of GFP did not affect structure and enzyme activity of cPLA2, the cPLA2-GFP construct was analyzed for AA release. The expression of cPLA2-GFP enhanced PAF-induced AA release in PAF11 cells by about 1.5-fold at 10 min. The correlation of AA release with the duration of [Ca2+]i increase was essentially identical to that in untransfected or GFP-transfected cells (Fig. 5, C and E). In addition, gel shift of cPLA2-GFP in response to agonist stimulation was comparable with that of endogenous cPLA2 (data not shown). The gel shift has been established to result from phosphorylation at Ser-505 (7). These results suggest that the fusion of GFP to the carboxyl terminus of cPLA2 does not perturb cPLA2 function.

We then monitored the localization of the cPLA2-GFP in living cells by confocal laser fluorescence microscopy. In the resting state, cPLA2-GFP was almost homogeneously present in the cytosol (Fig. 6, A and B, 0 min). Stimulation of the cells with PAF or ionomycin triggered translocation of cPLA2-GFP to the perinuclear region within 1 min, and the cPLA2-GFP fluorescence was retained for over 10 min (Fig. 6, A and B). When PAF12 cells transiently expressing cPLA2-GFP were stimulated with PAF, the translocation of cPLA2-GFP to the perinuclear region was transient and reversed within 5 min (Fig. 6C). In contrast to cPLA2-GFP, unconjugated GFP was distributed homogeneously in the cytosol and nucleus, and its distribution was not affected by PAF or ionomycin (data not shown).


View larger version (121K):
[in this window]
[in a new window]
 
Fig. 6.   Translocation of cPLA2-GFP fusion protein by PAF or ionomycin. PAF11 cells (A and B) and PAF12 cells (C) transiently transfected with the expression vector for cPLA2-GFP were serum-starved overnight and stimulated with 100 nM PAF (A and C) or 7.5 µM ionomycin (B). Confocal fluorescence images were recorded at the indicated time. The scale bars are 20 µm.

Next, the effect of termination of [Ca2+]i increase by EGTA on PAF-induced translocation of cPLA2-GFP was examined. cPLA2-GFP translocation was reversed rapidly when EGTA was added 1 min after PAF stimulation (Fig. 7A, upper panels). In contrast, the reversal was much slower when EGTA was added 5 min after stimulation; a large portion of cPLA2-GFP was retained at the perinuclear region for another 5 min after the addition of EGTA (Fig. 7A, lower panels). Similar redistributions of cPLA2-GFP were obtained by application of ionomycin instead of PAF (Fig. 7B). These results agree with the finding that AA release was inhibited when EGTA was added 1 min after PAF application, while it was not inhibited after 5 min (Fig. 5C), which means that a prolonged [Ca2+]i increase for about 5 min induces stable localization of cPLA2 at the perinuclear region and continuous hydrolysis of AA from membrane phospholipids.


View larger version (89K):
[in this window]
[in a new window]
 
Fig. 7.   Redistribution of cPLA2-GFP by EGTA. PAF11 cells expressing cPLA2-GFP were treated as described in Fig. 6. 10 mM EGTA was added 1 (upper panels) or 5 min (lower panels) after stimulation with 100 nM PAF (A) or 10 µM ionomycin (B). The scale bars are 20 µm.


    DISCUSSION

cPLA2 plays a major role in releasing AA upon cell stimuli and in production of eicosanoids (10, 11, 26). This enzyme is activated by [Ca2+]i increases in physiological ranges. Although previous reports have shown by immunohistochemical and biochemical methods that cPLA2 is translocated to membranes in response to [Ca2+]i increases, the dynamic change of the enzyme localization in the living cell has not been reported. The question we addressed here was how different Ca2+ signaling patterns control cPLA2 translocation and AA release. We found that a critical time length of [Ca2+]i elevation is required for continuous membrane localization and full activation of cPLA2.

Optimal concentrations of PAF and LTB4 triggered comparable maximal increases in [Ca2+]i in CHO cell lines expressing PAF and/or LTB4 receptor. However, duration of the [Ca2+]i increase varied with the cell line (Fig. 1). Correlations between Ca2+ signaling pattern (transient or sustained) and response in AA release (Table I) raised the possibility that the agonist-induced Ca2+ signaling pattern is responsible for the release of AA. Calcium mobilization from internal stores and subsequent Ca2+ entry from the extracellular space are the two major components of Ca2+ signaling following activation of cell-surface receptors. The inability of PAF to induce AA release in Ca2+-free medium (Fig. 4A) or in the presence of Ca2+ channel blockers (Fig. 4B) indicates the critical role of Ca2+ influx in AA release. This is consistent with the previous observations, in which AA release has been linked to Ca2+ influx (21). Ca2+ entry across the plasma membrane occurs via voltage-, store-, or receptor-operated channels. Although the primary route of Ca2+ influx in CHO cells remains to be elucidated, 100 µM nifedipine, an L-type voltage-dependent Ca2+ channel blocker, had no apparent effects on the Ca2+ influx induced by PAF or LTB4 (data not shown).

Stimulation of PAF receptor exerts various responses, including inhibition of adenylyl cyclase, activations of MAPK, phosphatidylinositol 3-kinase, phospholipases C and D, and tyrosine kinases, as well as increase in [Ca2+]i (24, 32, 34, 35). Although MAPK was activated by PAF and LTB4 to about the same extent in PAF-LT cells (data not shown), LTB4 did not induce AA release (Table I), suggesting that MAPK activation with a transient [Ca2+]i increase is insufficient to induce AA release. The experiments using ionomycin and EGTA confirmed that a sustained [Ca2+]i increase is essential for AA release in CHO cells (Fig. 5D). The difference in the extent of AA release between PAF and ionomycin (Fig. 5, C and D) is probably due to phosphorylation of cPLA2 by MAPK. Whereas PAF induced MAPK activation (34) and mobility shift of cPLA2 in SDS-polyacrylamide gel electrophoresis (36), ionomycin did not activate MAPK or promote the gel shift of cPLA2 (data not shown). These results are consistent with the previous reports that phosphorylation of cPLA2 increases its intrinsic enzymatic activity (7, 37, 38) and augments Ca2+-induced AA release (26, 39). It was recently reported that, in mouse peritoneal macrophages, the effects of phosphorylation of cPLA2 on AA release differ depending on whether calcium response is transient or sustained (40). Further studies are necessary to identify fully the individual and combined roles of calcium and phosphorylation for the activation of cPLA2 in various types of cells.

Calcium-mediated translocation of heterologously expressed cPLA2 to the nuclear envelope and endoplasmic reticulum was shown previously in CHO cells using an anti-cPLA2 antibody (14). Because immunohistochemical studies provide only a static picture and have a possible loss in signal linearity due to fixation, permeabilization, and staining of the cells, we took advantage of the GFP fusion protein and digital imaging technique to monitor cPLA2 translocation in real time in living cells. Although the endoplasmic reticulum forms a fine reticular network throughout the cytoplasm and around the nuclear envelope in CHO cells (41), cPLA2-GFP was translocated upon [Ca2+]i increase to a restricted space at the perinuclear region including the nuclear envelope (Figs. 6 and 7). This observation may be consistent with the study in rat alveolar epithelial cells, in which stimulation with a calcium ionophore A23187 induced translocation of cPLA2 to the nuclear membrane fraction and preferential loss of AA from this membrane fraction (42). Therefore, functional activation of cPLA2 takes place after translocation to the perinuclear region. Mechanisms involved in the preferential targeting of the enzyme to this site are under investigation.

Another important finding of the present study is that a brief [Ca2+]i rise caused a transient translocation of cPLA2 without AA release, whereas an increase in [Ca2+]i of longer duration (~5 min) induced a prolonged translocation of cPLA2 and AA release even after [Ca2+]i returned to the resting level (Figs. 5 and 7). To explain these observations, we propose a two-step mechanism for cPLA2 activation. In the initial step, cPLA2 is translocated to the perinuclear region upon increase in [Ca2+]i and weakly binds to the membranes. The enzyme is not yet activated, and the translocation can be readily reversed upon decrease in [Ca2+]i. In the second step, the binding of cPLA2 to the membranes becomes stronger with a marked reduction in the dissociation rate. Concomitantly, the enzyme is activated. The transfer from the first step to the second requires a critical length of continuous [Ca2+]i increase. The critical duration of [Ca2+]i increase was ~2 min in PAF11 cells but may differ depending on the cell type and the level of cPLA2 expression. Possible mechanisms by which cPLA2 is transferred from the weak-binding state to the strong-binding state include conformational change of cPLA2 by phosphorylation (7), dissociation of inhibitory proteins such as p11 (43), and interaction with anchoring or activating factors (44). The requirement of critical duration of [Ca2+]i increase for the activation of cPLA2 may serve as a safety mechanism to discriminate appropriate signals from transient fluctuations of [Ca2+]i. Once the [Ca2+]i transient exceeds the critical duration, the strong-binding state of cPLA2 allows the cells to produce AA for prolonged periods even after [Ca2+]i returns to the resting value.

    ACKNOWLEDGEMENTS

We thank Drs. H. Hanaka and T. Izumi for plasmids; Dr. Y. Kaziro and other laboratory members (University of Tokyo and Tokyo Institute of Technology) for valuable discussions; and M. Ohara for comments.

    FOOTNOTES

* This work was supported in part by grants-in-aid from the Ministry of Education, Science, Sports and Culture, CREST of Japan Science and Technology, and the Human Science Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

parallel To whom correspondence should be addressed: Dept. of Biochemistry and Molecular Biology, Faculty of Medicine, University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan. Tel.: 81-3-5802-2925; Fax: 81-3-3813-8732; E-mail: tshimizu{at}m.u-tokyo.ac.jp.

    ABBREVIATIONS

The abbreviations used are: AA, arachidonic acid; CHO, Chinese hamster ovary; [Ca2+]i, intracellular Ca2+ concentration; PLA2, phospholipase A2; cPLA2, cytosolic phospholipase A2; MAPK, mitogen-activated protein kinase; PAF, platelet-activating factor; LTB4, leukotriene B4; GFP, green fluorescent protein; BSA, bovine serum albumin.

    REFERENCES
Top
Abstract
Introduction
References
  1. Irvine, R. F. (1982) Biochem. J. 204, 3-16[Medline] [Order article via Infotrieve]
  2. Clark, J. D., Schievella, A. R., Nalefski, E. A., and Lin, L.-L. (1995) J. Lipid Mediat. Cell Signal. 12, 83-117[CrossRef][Medline] [Order article via Infotrieve]
  3. Dennis, E. A. (1997) Trends Biochem. Sci. 22, 1-2[CrossRef][Medline] [Order article via Infotrieve]
  4. Tischfield, J. A. (1997) J. Biol. Chem. 272, 17247-17250[Free Full Text]
  5. Balsinde, J., and Dennis, E. A. (1997) J. Biol. Chem. 272, 16069-16072[Free Full Text]
  6. Clark, J. D., Lin, L.-L., Kriz, R. W., Ramesha, C. S., Sultzman, L. A., Lin, A. Y., Milona, N., and Knopf, J. L. (1991) Cell 65, 1043-1051[Medline] [Order article via Infotrieve]
  7. Lin, L.-L., Wartmann, M., Lin, A. Y., Knopf, J. L., Seth, A., and Davis, R. J. (1993) Cell 72, 269-278[Medline] [Order article via Infotrieve]
  8. Kramer, R. M., and Sharp, J. D. (1997) FEBS Lett. 410, 49-53[CrossRef][Medline] [Order article via Infotrieve]
  9. Leslie, C. C. (1997) J. Biol. Chem. 272, 16709-16712[Free Full Text]
  10. Uozumi, N., Kume, K., Nagase, T., Nakatani, N., Ishii, S., Tashiro, F., Komagata, Y., Maki, K., Ikuta, K., Ouchi, Y., Miyazaki, J., and Shimizu, T. (1997) Nature 390, 618-622[CrossRef][Medline] [Order article via Infotrieve]
  11. Bonventre, J. V., Huang, Z., Taheri, M. R., O'Leary, E., Li, E., Moskowitz, M. A., and Sapirstein, A. (1997) Nature 390, 622-625[CrossRef][Medline] [Order article via Infotrieve]
  12. Nalefski, E. A., and Falke, J. J. (1996) Protein Sci. 5, 2375-2390[Abstract/Free Full Text]
  13. Glover, S., Bayburt, T., Jonas, M., Chi, E., and Gelb, M. H. (1995) J. Biol. Chem. 270, 15359-15367[Abstract/Free Full Text]
  14. Schievella, A. R., Regier, M. K., Smith, W. L., and Lin, L.-L. (1995) J. Biol. Chem. 270, 30749-30754[Abstract/Free Full Text]
  15. Rollins, T. E., and Smith, W. L. (1980) J. Biol. Chem. 255, 4872-4875[Abstract/Free Full Text]
  16. Serhan, C. N., Haeggström, J. Z., and Leslie, C. C. (1996) FASEB J. 10, 1147-1158[Abstract/Free Full Text]
  17. Spencer, A. G., Woods, J. W., Arakawa, T., Singer, I. I., and Smith, W. L. (1998) J. Biol. Chem. 273, 9886-9893[Abstract/Free Full Text]
  18. Woods, J. W., Evans, J. F., Ethier, D., Scott, S., Vickers, P. J., Hearn, L., Heibein, J. A., Charleson, S., and Singer, I. (1993) J. Exp. Med. 178, 1935-1946[Abstract]
  19. Goetzl, E. J., An, S., and Smith, W. L. (1995) FASEB J. 9, 1051-1058[Abstract/Free Full Text]
  20. Penrose, J. F., Spector, J., Lam, B. K., Friend, D. S., Xu, K., Jack, R. M., and Austen, K. F. (1995) Am. J. Respir. Crit. Care Med. 152, 283-289[Abstract]
  21. Brooks, R. C., McCarthy, K. D., Lapetina, E. G., and Morell, P. (1989) J. Biol. Chem. 264, 20147-20153[Abstract/Free Full Text]
  22. Krump, E., Pouliot, M., Naccache, P. H., and Borgeat, P. (1995) Biochem. J. 310, 681-688[Medline] [Order article via Infotrieve]
  23. Miyakawa, T., Kojima, M., and Ui, M. (1998) Biochem. J. 329, 107-114[Medline] [Order article via Infotrieve]
  24. Honda, Z., Nakamura, M., Miki, I., Minami, M., Watanabe, T., Seyama, Y., Okado, H., Toh, H., Ito, K., Miyamoto, T., and Shimizu, T. (1991) Nature 349, 342-346[CrossRef][Medline] [Order article via Infotrieve]
  25. Yokomizo, T., Izumi, T., Chang, K., Takuwa, Y., and Shimizu, T. (1997) Nature 387, 620-624[CrossRef][Medline] [Order article via Infotrieve]
  26. Lin, L.-L., Lin, A. Y., and Knopf, J. L. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 6147-6151[Abstract]
  27. Vial, D., and Piomelli, D. (1995) J. Neurochem. 64, 2765-2772[Medline] [Order article via Infotrieve]
  28. Takano, T., Honda, Z., Sakanaka, C., Izumi, T., Kameyama, K., Haga, K., Haga, T., Kurokawa, K., and Shimizu, T. (1994) J. Biol. Chem. 269, 22453-22458[Abstract/Free Full Text]
  29. Ishii, I., Izumi, T., Tsukamoto, H., Umeyama, H., Ui, M., and Shimizu, T. (1997) J. Biol. Chem. 272, 7846-7854[Abstract/Free Full Text]
  30. Gusovsky, F., Lueders, J. E., Kohn, E. C., and Felder, C. C. (1993) J. Biol. Chem. 268, 7768-7772[Abstract/Free Full Text]
  31. Kley, N., Loeffler, J. P., Pittius, C. W., and Hollt, V. (1987) J. Biol. Chem. 262, 4083-4089[Abstract/Free Full Text]
  32. Izumi, T., and Shimizu, T. (1995) Biochim. Biophys. Acta 1259, 317-333[Medline] [Order article via Infotrieve]
  33. Cubitt, A. B., Heim, R., Adams, S. R., Boyd, A. E., Gross, L. A., and Tsien, R. Y. (1995) Trends Biochem. Sci. 20, 448-455[CrossRef][Medline] [Order article via Infotrieve]
  34. Honda, Z., Takano, T., Gotoh, Y., Nishida, E., Ito, K., and Shimizu, T. (1994) J. Biol. Chem. 269, 2307-2315[Abstract/Free Full Text]
  35. Stephens, L., Jackson, T., and Hawkins, P. T. (1993) J. Biol. Chem. 268, 17162-17172[Abstract/Free Full Text]
  36. Sakanaka, C., Ferby, I., Waga, I., Bito, H., and Shimizu, T. (1994) Biochem. Biophys. Res. Commun. 205, 18-23[CrossRef][Medline] [Order article via Infotrieve]
  37. Nemenoff, R. A., Winitz, S., Qian, N.-X., Van Putten, V., Johnson, G. L., and Heasley, L. E. (1993) J. Biol. Chem. 268, 1960-1964[Abstract/Free Full Text]
  38. Kramer, R. M., Roberts, E. F., Manetta, J. V., Hyslop, P. A., and Jakubowski, J. A. (1993) J. Biol. Chem. 268, 26796-26804[Abstract/Free Full Text]
  39. Xu, X. X., Rock, C. O., Qiu, Z.-H., Leslie, C. C., and Jackowski, S. (1994) J. Biol. Chem. 269, 31693-31700[Abstract/Free Full Text]
  40. Qiu, Z.-H., Gijon, M. A., de Carvalho, M. S., Spencer, D. M., and Leslie, C. C. (1998) J. Biol. Chem. 273, 8203-8211[Abstract/Free Full Text]
  41. Náray-Fejes-Tóth, A., and Fejes-Tóth, G. (1996) J. Biol. Chem. 271, 15436-15442[Abstract/Free Full Text]
  42. Peters-Golden, M., Song, K., Marshall, T., and Brock, T. (1996) Biochem. J. 318, 797-803[Medline] [Order article via Infotrieve]
  43. Wu, T., Angus, C. W., Yao, X. L., Logun, C., and Shelhamer, J. H. (1997) J. Biol. Chem. 272, 17145-17153[Abstract/Free Full Text]
  44. Mosior, M., Six, D. A., and Dennis, E. A. (1998) J. Biol. Chem. 273, 2184-2191[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.